• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
  

PubMed=2323006; DOI=10.1093/carcin/11.4.673
Pelin-Enlund K., Husgafvel-Pursiainen K., Tammilehto L., Klockars M., Jantunen K., Gerwin B.I., Harris C.C., Tuomi T., Vanhala E., Mattson K., Linnainmaa K.
Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.
Carcinogenesis 11:673-681(1990)

PubMed=1568228
Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I., Harris C.C.
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Cancer Res. 52:2610-2615(1992)

PubMed=9533946; DOI=10.1165/ajrcmb.18.4.2943
Kahlos K., Anttila S., Asikainen T.M., Kinnula K., Raivio K.O., Mattson K., Linnainmaa K., Kinnula V.L.
Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma.
Am. J. Respir. Cell Mol. Biol. 18:570-580(1998)

CLPUB00243
Kahlos K.
The expression and possible role of manganese superoxide dismutase in malignant pleural mesothelioma.
Thesis PhD (1999); University of Oulu; Oulu; Finland

PubMed=11251971; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M
Kettunen E., Nissen A.-M., Ollikainen T., Taavitsainen M., Tapper J., Mattson K., Linnainmaa K., Knuutila S., El-Rifai W.
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study.
Int. J. Cancer 91:492-496(2001)

PubMed=11283936; DOI=10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D
Kahlos K., Soini Y., Sormunen R., Kaarteenaho-Wiik R., Paakko P., Linnainmaa K., Kinnula V.L.
Expression and prognostic significance of catalase in malignant mesothelioma.
Cancer 91:1349-1357(2001)

PubMed=23840376; DOI=10.1371/journal.pone.0065903; PMCID=PMC3688685
Szulkin A., Nilsonne G., Mundt F., Wasik A.M., Souri P., Hjerpe A., Dobra K.
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
PLoS ONE 8:e65903.1-e65903.14(2013)

PubMed=33567673; DOI=10.3390/cancers13040685; PMCID=PMC7915464
Keller M., Reis K., Hjerpe A., Dobra K., Aspenstrom P.
Cytoskeletal organization correlates to motility and invasiveness of malignant mesothelioma cells.
Cancers (Basel) 13:685.1-685.20(2021)